NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.

Melanoma is one of the most aggressive cancers and its incidence is increasing worldwide. So far there are no curable therapies especially after metastasis. Due to frequent mutations in members of the mitogen-activated protein kinase (MAPK) signaling pathway, this pathway is constitutively active in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ahmad Jalili, Kirsten D Mertz, Julia Romanov, Christine Wagner, Frank Kalthoff, Anton Stuetz, Gaurav Pathria, Melanie Gschaider, Georg Stingl, Stephan N Wagner
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/9c2af3532f6f4c2db3d5beaf636d21d8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!